Active	Status	Sponsor type	Region	Phase	Filter
8 Active 14 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
obefazimod (ABX464) / Abivax
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Recruiting	3	612	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
NCT03368118 / 2017-003284-35: Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis	Completed	2	22	Europe	ABX464	Abivax S.A., Orion Corporation, Orion Pharma	Ulcerative Colitis	07/22	08/22
NCT04023396 / 2019-000733-39: Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis	Completed	2	217	Europe, Canada, RoW	ABX464, Obefazimod	Abivax S.A.	Ulcerative Colitis	02/23	03/24
ABX464-108, NCT05177835 / 2021-004398-30: Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis	Active, not recruiting	2	203	Europe, RoW	ABX464	Abivax S.A., Abivax, ABIVAX	Ulcerative Colitis	02/27	04/27
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease	Recruiting	2	212	Europe, US, RoW	Obefazimod, Placebo	Abivax S.A.	Moderately to Severely Active Crohn Disease	12/26	04/28
ABX196 / Abivax
NCT03897543: ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma	Recruiting	1/2	48	US	ABX196	Abivax S.A., C3 Research Associates	Carcinoma, Hepatocellular	06/21	06/23
ABX544 / Abivax, ExpreS2ion
No trials found
ABX311 / Abivax
No trials found
ABX 220 / Abivax, Heber Biotec
No trials found
HeberNasvac (ABX203) / Center for Genetic Engineering and Biotechnology, Abivax
No trials found
ABX-318 / Abivax
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
obefazimod (ABX464) / Abivax
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Recruiting	3	612	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
NCT03368118 / 2017-003284-35: Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis	Completed	2	22	Europe	ABX464	Abivax S.A., Orion Corporation, Orion Pharma	Ulcerative Colitis	07/22	08/22
NCT04023396 / 2019-000733-39: Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis	Completed	2	217	Europe, Canada, RoW	ABX464, Obefazimod	Abivax S.A.	Ulcerative Colitis	02/23	03/24
ABX464-108, NCT05177835 / 2021-004398-30: Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis	Active, not recruiting	2	203	Europe, RoW	ABX464	Abivax S.A., Abivax, ABIVAX	Ulcerative Colitis	02/27	04/27
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease	Recruiting	2	212	Europe, US, RoW	Obefazimod, Placebo	Abivax S.A.	Moderately to Severely Active Crohn Disease	12/26	04/28
ABX196 / Abivax
NCT03897543: ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma	Recruiting	1/2	48	US	ABX196	Abivax S.A., C3 Research Associates	Carcinoma, Hepatocellular	06/21	06/23
ABX544 / Abivax, ExpreS2ion
No trials found
ABX311 / Abivax
No trials found
ABX 220 / Abivax, Heber Biotec
No trials found
HeberNasvac (ABX203) / Center for Genetic Engineering and Biotechnology, Abivax
No trials found
ABX-318 / Abivax
No trials found